Elexacaftor–Tezacaftor–Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis
The Laryngoscope · 2026-05 · 136 (5) · 2048-2053
DOI: 10.1002/lary.70283 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 04.12.2025. Verfasst von Amy Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University, College of Medicine, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Aminophenols, Quinolones. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
To assess whether elexacaftor–tezacaftor–ivacaftor (ETI) reduces the frequency of endoscopic sinus surgeries (ESS) in patients with cystic fibrosis (pwCF).
Methods
We conducted a retrospective chart review of pwCF aged 6 years and older who received ETI between January 1, 2018 and December 31, 2023. Inclusion criteria required a history of ESS and a follow‐up time of at least 2 years before and after ETI initiation. Records were reviewed from up to 8 years prior to ETI through the most recent visit. The total number and frequency of ESS were evaluated using univariable linear models, estimating mean difference with 95% confidence intervals (CI) and p ‐values.
Results
Fifty‐six patients met inclusion criteria, with a median follow‐up time of 8 years (IQR: 8, 8) before ETI initiation and 4.13 years (IQR: 3.47, 4.78) after initiation of ETI. Median age at ETI initiation was 13 years (IQR: 10, 23). Among these patients, 98% ( n = 55) required ESS prior to ETI, compared to 21% ( n = 12) after ETI. The average number of sinus surgeries decreased from 2.88 ± 1.68 before ETI to 0.30 ± 0.63 after ETI (mean difference: 2.6; 95% CI: [2.1, 3.1]; p < 0.001). The frequency of surgeries per year dropped from 0.37 ± 0.22 to 0.07 ± 0.15 after beginning ETI (mean difference: 0.30; 95% CI: [0.23, 0.37]; p < 0.001).
Conclusion
ETI was associated with a significant decrease in the frequency and rate of ESS in pwCF. These findings suggest an improvement in CF‐related chronic rhinosinusitis outcomes following ETI and may influence future CF treatment decisions. Level of Evidence 4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ohio State University, College of Medicine, Columbus, Ohio, USA.
- Department of Otolaryngology-Head and Neck Surgery, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Center for Biostatistics, the Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Biostatistics Resource at Nationwide Children's Hospital, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Pulmonary, Sleep Medicine and Cystic Fibrosis, Nationwide Children's Hospital, Columbus, Ohio, USA.
ORCID-Profile: Zheng Hong Tan, Tendy Chiang
Zitieren
APA
Lin, A., Komara, M., Kistler, I., Tan, Z. H., Lind, M., Kotha, K., & Chiang, T. (2026). Elexacaftor–Tezacaftor–Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis. The Laryngoscope, 136(5), 2048-2053. https://doi.org/10.1002/lary.70283
Vancouver
Lin A, Komara M, Kistler I, Tan ZH, Lind M, Kotha K, et al. Elexacaftor–Tezacaftor–Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis. The Laryngoscope. 2026;136(5):2048-2053. doi:10.1002/lary.70283
BibTeX
@article{Lin2026,
author = {Lin, Amy and Komara, Makanko and Kistler, Isaac and Tan, Zheng Hong and Lind, Meredith and Kotha, Kavitha and Chiang, Tendy},
title = {Elexacaftor–Tezacaftor–Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis},
journal = {The Laryngoscope},
year = {2026},
volume = {136},
number = {5},
pages = {2048--2053},
doi = {10.1002/lary.70283}
}
EUVIMED